An orally bioavailable helicase-primase inhibitor; inhibits the ATPase activity of HSV helicase-primase (IC50 = 30 nM); inhibits HSV replication in Vero cells (IC50 = 20 nM for both HSV-1 and HSV-2); active against porcine and bovine HSV strains (IC50s = 5 and 0.12 μM, respectively); effective against HSV-1 and HSV-2 in a lethal challenge model (ED50 = 0.5 mg/kg in mice and rats) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats; reduces levels of Aβ and phosphorylated Tau production in HSV-1 infected Vero cells